Transamerica Financial Advisors Inc. Purchases Shares of 4,760 Sanofi (NASDAQ:SNY)

Transamerica Financial Advisors Inc. purchased a new stake in Sanofi (NASDAQ:SNY) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,760 shares of the company’s stock, valued at approximately $275,000.

Several other large investors also recently modified their holdings of SNY. POM Investment Strategies LLC acquired a new stake in shares of Sanofi during the second quarter worth $25,000. Northwest Investment Counselors LLC acquired a new stake in shares of Sanofi during the third quarter worth $29,000. Concord Wealth Partners increased its position in shares of Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after buying an additional 363 shares during the period. Arrow Financial Corp acquired a new stake in shares of Sanofi during the second quarter worth $35,000. Finally, Fortitude Family Office LLC grew its holdings in Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Down 0.1 %

Sanofi stock opened at $48.28 on Wednesday. Sanofi has a 1-year low of $45.22 and a 1-year high of $58.97. The firm has a market capitalization of $122.53 billion, a price-to-earnings ratio of 24.63, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. The firm’s fifty day moving average price is $53.35 and its two-hundred day moving average price is $52.17. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same period last year, the firm earned $2.55 earnings per share. The business’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, equities research analysts predict that Sanofi will post 4.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of research reports. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.